Compare MPLX LP (MPLX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Regeneron Pharmaceuticals Inc — how do they compare? MPLX LP trades at $59.3 (market cap $59.51B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and MPLX LP pays the higher dividend (7.34%). Which is the better fit depends on your goals.
| MPLX | REGN | |
|---|---|---|
Market Cap | $59.51B | $83.19B |
Sector | Technology | Health |
52-Week High | $60.51 | $812.27 |
52-Week Low | $47.80 | $555.51 |
Enterprise Value | $84.62B | $77.90B |
Dividend Yield | 7.34% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $58.85, down 2.6% today, with a bullish technical outlook supported by moving averages and strong institutional support. The company maintains robust profitability with 40.45% net income margin and 33.95% ROE, though recent quarters showed mixed earnings performance with two misses. Recent news highlights MPLX's $2.25 billion senior notes offering and solid Q2 2026 results with 5% EBITDA growth.
The stock presents a compelling income opportunity with a 7.3% yield and analyst consensus price target of $61.50 (4.5% upside). Key risks include execution challenges from higher capital spending and leverage concerns, while growth projects in natural gas and NGL services provide multi-year visibility.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
